Cargando…
Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive disease, with patients diagnosed with either early-stage, limited stage, or extensive stage of SCLC tumor progression. Discovering and targeting the functional biomarkers for SCLC will be crucial in understanding the molecular basis underlying SCLC tumo...
Autores principales: | Tsuboyama, Natsumi, Wang, Ru, Szczepanski, Aileen Patricia, Chen, Huanhuan, Zhao, Zibo, Shi, Lei, Wang, Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993689/ https://www.ncbi.nlm.nih.gov/pubmed/35194152 http://dx.doi.org/10.1038/s41388-022-02240-x |
Ejemplares similares
-
MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer
por: Tsuboyama, Natsumi, et al.
Publicado: (2022) -
ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer
por: Szczepanski, Aileen Patricia, et al.
Publicado: (2020) -
CARM1-mediated methylation of ASXL2 impairs tumor-suppressive function of MLL3/COMPASS
por: Zhao, Zibo, et al.
Publicado: (2022) -
Emerging multifaceted roles of BAP1 complexes in biological processes
por: Szczepanski, Aileen Patricia, et al.
Publicado: (2021) -
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018)